Accéder au contenu
Merck
Toutes les photos(1)

Documents

L-021

Supelco

Lorazepam glucuronide solution

100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H18Cl2N2O8
Numéro CAS:
32781-79-6
Poids moléculaire :
497.28
Numéro MDL:
MFCD02682126
Code UNSPSC :
41116107
ID de substance PubChem :
329817344
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

Concentration

100 μg/mL in acetonitrile: water (1:1)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3Cl)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1

Clé InChI

IWOJSSFCRQKNKN-IFBJMGMISA-N

Catégories apparentées

Description générale

Lorazepam glucuronide is a primary urinary metabolite of lorazepam, a benzodiazepine often prescribed for treatment of anxiety disorders. This Certified Spiking Solution® is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-901

Lorazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-902

Lorazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-907

Lormetazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-911

Lorazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

D-163

Delorazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

L-059

Lorazepam-D4 glucuronide lithium salt solution, 100 μg/mL (Acetonitrile:Water (50:50) (v/v), (as free acid)), certified reference material, ampule of 1 mL, Cerilliant®

Pictogrammes

FlameExclamation mark
GHS02,GHS07

Mention d'avertissement

Danger

Mentions de danger

H225,H302,H319

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

55.4 °F - closed cup

Point d'éclair (°C)

13 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

L L von Moltke et al.
Biopharmaceutics & drug disposition, 14(2), 119-130 (1993-03-01)
The effect of probenecid on glucuronidation of acetaminophen and lorazepam in hepatic microsomes from various species was studied to see if in vitro results were consistent with previous in vivo observations. Mouse, rat, and human microsomes were incubated with acetaminophen
Eleonora L Swart et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 45(2), 360-371 (2005-02-03)
The objective is to study the population pharmacokinetics of lorazepam and midazolam in critically ill patients with acute renal failure who are treated with continuous venovenous hemofiltration (CVVH). Twenty critically ill patients with acute renal failure on CVVH therapy were
Olga Papini et al.
Journal of pharmaceutical and biomedical analysis, 40(2), 397-403 (2005-09-07)
The present study investigates the kinetic disposition with focus on the racemization, glucuronidation capacity and the transplacental transfer of lorazepam in term parturients during labor. The study was conducted on 10 healthy parturients aged 18-37 years with a gestational age
G Morrison et al.
Clinical pharmacology and therapeutics, 35(5), 646-652 (1984-05-01)
The effect of renal disease on lorazepam kinetics was assessed in three groups: six normal subjects, six patients with renal impairment, and four functionally anephric patients. Subjects received single 1.5- or 3-mg intravenous and oral doses; eight subjects (four normal
R Verbeeck et al.
British journal of clinical pharmacology, 3(6), 1033-1039 (1976-12-01)
To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (CC(r) : less than 2 ml/min)
Afficher tous les articles scientifiques apparentés

Protocoles

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique